Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Extraintestinal manifestations (EIMs) are common in patients with ulcerative colitis (UC) and can have a significant impact on patient morbidity and quality of life. We assessed the effect of adalimumab (ADA) therapy on the resolution of EIMs among patients with moderate to severe UC in clinical pra...

Повний опис

Бібліографічні деталі
Автори:	Travis, S, Feagan, B, Peyrin-Biroulet, L, Panaccione, R, Danese, S, Lazar, A, Robinson, A, Thakkar, R, Pappalardo, B, Petersson, J, Bereswill, M, Chen, N, Skup, M
Формат:	Journal article
Опубліковано:	Oxford University Press 2017

Схожі ресурси

Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
за авторством: Travis, S, та інші
Опубліковано: (2017)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA
за авторством: Travis, S, та інші
Опубліковано: (2017)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results From InspirADA.
за авторством: Travis, S, та інші
Опубліковано: (2017)

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
за авторством: Sandborn, W, та інші
Опубліковано: (2016)

Does it all ADA up? Adalimumab for ulcerative colitis.
за авторством: Travis, S
Опубліковано: (2011)

Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?
за авторством: Walsh, A, та інші
Опубліковано: (2018)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
за авторством: Napolitano M, та інші
Опубліковано: (2022-06-01)

Immune Thrombocytopenic Purpura as an Extraintestinal Manifestation in a Patient with Ulcerative Colitis
за авторством: Renata de Medeiros Dutra, та інші
Опубліковано: (2022-03-01)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
за авторством: David T. Rubin, та інші
Опубліковано: (2021-05-01)

Raising the bar in ulcerative colitis management
за авторством: Fabrizio Fanizzi, та інші
Опубліковано: (2024-11-01)

Pulmonary Extraintestinal Manifestation of Crohn’s Disease Treated Successfully with Adalimumab
за авторством: Dongyeol Shin, та інші
Опубліковано: (2018-09-01)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
за авторством: Ferdinando D’Amico, та інші
Опубліковано: (2019-05-01)

A Case of Syrian Child with Cerebral Infarction as an Extraintestinal Manifestation of Ulcerative Colitis
за авторством: Riham Salloum, та інші
Опубліковано: (2019-01-01)

Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal Manifestations
за авторством: Yiyoung Kwon, та інші
Опубліковано: (2022-05-01)

Meta‐analysis of the association of extraintestinal manifestations with the development of pouchitis in patients with ulcerative colitis
за авторством: K. Hata, та інші
Опубліковано: (2019-08-01)

Role of Probiotics in the Management of Patients with Ulcerative Colitis and Pouchitis
за авторством: Francesca Bernardi, та інші
Опубліковано: (2024-12-01)

Multiple extraintestinal manifestations in a patient with acute severe ulcerative colitis: a case report
за авторством: Eun Young Park, та інші
Опубліковано: (2022-12-01)

Factors Associated with the Presence of Extraintestinal Manifestations in Patients with Ulcerative Colitis in a Latin American Country
за авторством: Jesús K. Yamamoto-Furusho, та інші
Опубліковано: (2020-10-01)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
за авторством: Eun Soo Kim
Опубліковано: (2021-03-01)

Febrile neutropenia associated with adalimumab in a patient with ulcerative colitis
за авторством: Ma’In Atallah Mohammad Abumuhfouz, та інші
Опубліковано: (2024-04-01)

Albumin change predicts failure in ulcerative colitis treated with adalimumab
за авторством: Natsuki Ishida, та інші
Опубліковано: (2024-01-01)

Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis
за авторством: Laurel L. Wessman, BS, та інші
Опубліковано: (2017-07-01)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
за авторством: Assasi Nazila, та інші
Опубліковано: (2009-12-01)

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
за авторством: Armuzzi A, та інші
Опубліковано: (2013-04-01)

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
за авторством: Freeman HJ
Опубліковано: (2013-11-01)

Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis
за авторством: Zhdanava M, та інші
Опубліковано: (2024-04-01)

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
за авторством: Vuitton, L, та інші
Опубліковано: (2017)

Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
Опубліковано: (2016-03-01)

Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis
за авторством: Sebastian Hoffmann, та інші
Опубліковано: (2018-05-01)

ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY
за авторством: Patrícia ZACHARIAS, та інші
Опубліковано: (2017-10-01)

Leukocytoclastic Vasculitis as a Rare Dermatologic Extraintestinal Manifestation of Ulcerative Colitis in an Elderly Patient with Positive PR3-ANCA
за авторством: Jacky Ng, та інші
Опубліковано: (2021-01-01)

Exploring genetic associations of Crohn’s disease and ulcerative colitis with extraintestinal cancers in European and East Asian populations
за авторством: Chengdong Yu, та інші
Опубліковано: (2024-02-01)

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
за авторством: Shinji Okabayashi, та інші
Опубліковано: (2017-10-01)

Comparison of long-term outcomes of infliximab and adalimumab therapy in biologic-naive patients with ulcerative colitis
за авторством: Muhammed B. Durak, та інші
Опубліковано: (2025-01-01)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
за авторством: Bénédicte Caron, та інші
Опубліковано: (2023-01-01)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
за авторством: Travis, S, та інші
Опубліковано: (2012)

Henoch-Schönlein Purpura with Adalimumab Therapy for Ulcerative Colitis: A Case Report and Review of the Literature
за авторством: Joseph J. LaConti, та інші
Опубліковано: (2016-01-01)

Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis
за авторством: Saleh Azadbakht, та інші
Опубліковано: (2024-07-01)

Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
за авторством: Candace L. Beilman, та інші
Опубліковано: (2016-01-01)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring.
за авторством: Martin Wasserbauer, та інші
Опубліковано: (2022-01-01)